New asthma treatment guidelines could be good news for drug companies. The government advises better day-to-day control of the disease--and that probably means more widespread use of inhaled corticosteroid drugs such as Flovent (GlaxoSmithKline), Azmacort (Sanofi-Aventis), and Pulmicort (AstraZeneca).
For patients with severe asthma, the National Institutes of Health report also recommends Omalizumab, a Genentech/Novartis drug sold under the brand name Xolair, which targets antibodies that can cause asthma symptoms.
Scientists find link between colds and asthma attacks. Report
FDA rejects GSK's Advair for COPD. Report
NIH budget cuts cause alarm in research circles. Report